These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 22925075)

  • 1. ROCKs as immunomodulators of stroke.
    Wang QM; Liao JK
    Expert Opin Ther Targets; 2012 Oct; 16(10):1013-25. PubMed ID: 22925075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROCK as a therapeutic target for ischemic stroke.
    Sladojevic N; Yu B; Liao JK
    Expert Rev Neurother; 2017 Dec; 17(12):1167-1177. PubMed ID: 29057688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.
    Zhou Q; Gensch C; Liao JK
    Trends Pharmacol Sci; 2011 Mar; 32(3):167-73. PubMed ID: 21242007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cerebrovascular Rho-kinase in stroke.
    Shin HK; Salomone S; Ayata C
    Expert Opin Ther Targets; 2008 Dec; 12(12):1547-64. PubMed ID: 19007322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rho Kinases in Autoimmune Diseases.
    Pernis AB; Ricker E; Weng CH; Rozo C; Yi W
    Annu Rev Med; 2016; 67():355-74. PubMed ID: 26768244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho-kinase: important new therapeutic target in cardiovascular diseases.
    Satoh K; Fukumoto Y; Shimokawa H
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
    Dong M; Yan BP; Yu CM
    Cardiovasc Hematol Agents Med Chem; 2009 Oct; 7(4):322-30. PubMed ID: 19607644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
    Knipe RS; Tager AM; Liao JK
    Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rho kinase: an important mediator of atherosclerosis and vascular disease.
    Zhou Q; Liao JK
    Curr Pharm Des; 2009; 15(27):3108-15. PubMed ID: 19754385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striking crosstalk of ROCK signaling with endothelial function.
    Noma K; Kihara Y; Higashi Y
    J Cardiol; 2012 Jul; 60(1):1-6. PubMed ID: 22607993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor.
    Holvoet T; Devriese S; Castermans K; Boland S; Leysen D; Vandewynckel YP; Devisscher L; Van den Bossche L; Van Welden S; Dullaers M; Vandenbroucke RE; De Rycke R; Geboes K; Bourin A; Defert O; Hindryckx P; De Vos M; Laukens D
    Gastroenterology; 2017 Oct; 153(4):1054-1067. PubMed ID: 28642198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological role of ROCKs in the cardiovascular system.
    Noma K; Oyama N; Liao JK
    Am J Physiol Cell Physiol; 2006 Mar; 290(3):C661-8. PubMed ID: 16469861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ROCK signaling in health, malignant and non-malignant diseases.
    Shahbazi R; Baradaran B; Khordadmehr M; Safaei S; Baghbanzadeh A; Jigari F; Ezzati H
    Immunol Lett; 2020 Mar; 219():15-26. PubMed ID: 31904392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROCKs as therapeutic targets in cardiovascular diseases.
    Rikitake Y; Liao JK
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):441-51. PubMed ID: 15889972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
    Shimokawa H; Satoh K
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.
    Yu B; Sladojevic N; Blair JE; Liao JK
    Expert Opin Ther Targets; 2020 Jan; 24(1):47-62. PubMed ID: 31906742
    [No Abstract]   [Full Text] [Related]  

  • 17. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
    Abbhi V; Piplani P
    Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functions of Rho family of small GTPases and Rho-associated coiled-coil kinases in bone cells during differentiation and mineralization.
    Strzelecka-Kiliszek A; Mebarek S; Roszkowska M; Buchet R; Magne D; Pikula S
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1009-1023. PubMed ID: 28188861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Rho-kinase inhibitors for cardiovascular medicine.
    Shimokawa H; Rashid M
    Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating Astrocyte Transition after Stroke to Promote Brain Rescue and Functional Recovery: Emerging Targets Include Rho Kinase.
    Abeysinghe HC; Phillips EL; Chin-Cheng H; Beart PM; Roulston CL
    Int J Mol Sci; 2016 Feb; 17(3):288. PubMed ID: 26927079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.